Research and Clinical Trials

Laboratory and Translational Research in the John C. Davis Program

Translational studies are a fundamental aspect of the modern treatment of plasma cell diseases. A major focus of our research is identifying the genes and proteins that enable malignant plasma cells to cause disease and to survive despite modern treatments. The SAVE trial for patients with lambda smoldering myeloma or monoclonal gammopathy of undetermined significance helps patients to be diagnosed before they are sick by identifying the light-chain genes in their plasma cells. Furthermore, as patients are treated and go into remission, we also provide the opportunity for them to have minimal residual disease studies performed in order to guide therapy. Minimal residual disease studies help us to characterize the effectiveness of therapy and the durability of complete responses. Patients with relapsed refractory myeloma who receive ACTR T-cell therapy (similar to CAR-T cell therapy) can also be followed with minimal residual disease testing.  

Our research staff handles the bone marrow, blood and stem cells of patients willing to donate to advance our knowledge these diseases. For minimal residual disease testing we employ a state-of-the-art genetic test that is performed on bone marrow cells from diagnosis and at the time of achieving a complete response.

Clinical Trials

These clinical trials are currently open and recruiting patients at Tufts MC:

For multiple myeloma:

A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with
Relapsed or Refractory Multiple Myeloma

For systemic AL amyloidosis:

A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early

Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients with AL Amyloidosis

A Phase 3, Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients with Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

A Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis